FDA conducts inspection of Mahana Therapeutics, Inc. in San Francisco on Aug. 13, 2024

Vid Desai FDA’s Chief Information Officer
Vid Desai FDA’s Chief Information Officer - Official Website
0Comments

The Food and Drug Administration carried out an inspection of Mahana Therapeutics, Inc., located in San Francisco, on August 13, 2024, according to data posted on the FDA’s website.

The inspection covered the following areas:

  • Compliance: Devices
  • Postmarket Assurance: Devices

The FDA’s final report concluded that Mahana Therapeutics, Inc. was not required to implement any corrective actions regarding its management operations.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.

Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.



Related

Dr. Mehmet Oz CMS Administrator

San Mateo Medicaid Evaluation and Management payments amount to $13.8 million in 2024

San Mateo’s Medicaid payments for Evaluation and Management services climbed by 19.5% in 2024, signaling shifts in service use and payment practices.

Dr. Mehmet Oz CMS Administrator

Surgery services in San Francisco see $6,619,911 in Medicaid payments for 2024

In 2024, Medicaid providers in San Francisco submitted $6,619,911 in claims categorized as Surgery services, representing a 150.5% rise from the prior year.

Anthony DiGiorgio, Assistant Professor of Neurological Surgery, UCSF

UCSF Assistant Professor DiGiorgio on 340B: ‘340B has helped crush independent oncology practice’

UCSF Assistant Professor Anthony DiGiorgio said on May 13 that the federal 340B program disadvantages independent oncology practices by giving large hospital systems access to steeply discounted drugs.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from San Francisco Sun.